Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification

Journal of Clinical Pathology

Volumn 65, Issue 3, 2012, Pages 193-199

  Cserni, Gábor ^a  

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; MESSENGER RNA;

BREAST CANCER; CANCER STAGING; FALSE NEGATIVE RESULT; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; MICROMETASTASIS; NUCLEIC ACID AMPLIFICATION; ONE STEP NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE; TUMOR VOLUME;

BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE CARE; KERATIN-19; LYMPH NODES; NEOPLASM METASTASIS; NEOPLASM STAGING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 84857370817     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200301     Document Type: Review

References (65)

1. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-20. (Pubitemid 46291835)
2. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-401.
3. Tew K, Irving L, Matthews A, et al. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg 2005;92:1068-80. (Pubitemid 41284870)
4. Liu LC, Lang JE, Lu Y, et al. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients. Cancer 2011;117:250-8.
5. Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999;85:2433-8. (Pubitemid 29244852)
6. Ku NN. Pathologic examination of sentinel lymph nodes in breast cancer. Surg Oncol Clin North Am 1999;8:469-79. (Pubitemid 29321216)
7. Salem AA, Douglas-Jones AG, Sweetland HM, et al. Intraoperative evaluation of axillary sentinel lymph nodes using touch imprint cytology and immunohistochemistry. Part II. Results. Eur J Surg Oncol 2006;32:484-7.
8. Nahrig JM, Richter T, Kuhn W, et al. Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry. Breast J 2003;9:277-81. (Pubitemid 36927406)
9. Leikola JP, Tolvonen TS, Krogerus LA, et al. Rapid immunohistochemistry enhances the intraoperative diagnosis of sentinel lymph node metastases in invasive lobular breast carcinoma. Cancer 2005;104:14-19. (Pubitemid 40847747)
10. Choi YJ, Yun HR, Yoo KE, et al. Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry in breast cancer. Jpn J Clin Oncol 2006;36:489-93. (Pubitemid 44592676)
11. Blumencranz P, Whitworth PW, Deck K, et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007;194:426-32. (Pubitemid 47370997)
12. Tsujimoto M, Nakabayashi K, Yoshidome K, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 2007;13:4807-16. (Pubitemid 47294788)
13. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000;28:E63.
14. Le Frère-Belda MA, Bats AS, Gillaizeau F, et al. Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. Int J Cancer. Published Online First: 21 July 2011. doi:10.1002/ijc.26291.
15. Sobin L, Gospodarowicz M, Wittekind Ch, eds. UICC TNM Classification of Malignant Tumours, 7th edn. New York: John Wiley and Sons Inc, 2009.
16. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer, 2009.
17. Cserni G, Amendoeira I, Apostolikas N, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire-based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 2004;57:695-701. (Pubitemid 38901482)
18. Snook KL, Layer GT, Jackson PA, et al. Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg 2011;98:527-35.
19. Osako T, Iwase T, Kimura K, et al. Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between onestep nucleic acid amplification whole node assay and routine frozen section histology. Cancer 2011;117(19):4365-74.
20. Smith PA, Harlow SP, Krag DN, et al. Submission of lymph node tissue for ancillary studies decreases the accuracy of conventional breast cancer axillary node staging. Mod Pathol 1999;12:781-5. (Pubitemid 29383881)
21. Cserni G. Mapping metastases in sentinel lymph nodes of breast cancer. Am J Clin Pathol 2000;113:351-4. (Pubitemid 30217381)
22. Diaz LK, Hunt K, Ames F, et al. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol 2003;27:385-9. (Pubitemid 36245804)
23. Daniele L, Annaratone L, Allia E, et al. Technical limits of comparison of step-sectioning, immunohistochemistry and RTePCR on breast cancer sentinel nodes: a study on methacarn fixed tissue. J Cell Mol Med 2009;13:4042-50.
24. Visser M, Jiwa M, Horstman A, et al. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 2008;122:2562-7. (Pubitemid 351590490)
25. Schem C, Maass N, Bauerschlag DO, et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch 2009;454:203-10.
26. Tamaki Y, Akiyama F, Iwase T, et al. Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 2009;15:2879-84.
27. Feldman S, Krishnamurthy S, Gillanders W, et al. A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 2011;117:2599-607.
28. Bernet L, Cano R, Martinez M, et al. Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. Histopathology 2011;58:863-9.
29. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39. (Pubitemid 34535443)
30. Alvarenga CA, Paravidino PI, Alvarenga M, et al. Expression of CK19 in invasive breast carcinomas of special histological types: implications for the use of one-step nucleic acid amplification. J Clin Pathol 2011;64:493-7.
31. Maiorano E, Mazzarol GM, Pruneri G, et al. Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies. Am J Surg Pathol 2003;27:513-18. (Pubitemid 36368550)
32. Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol 2006;24:2013-18. (Pubitemid 46622109)
33. Yun K, Gunn J, Merrie AE, et al. Keratin 19 mRNA is detectable by RTePCR in lymph nodes of patients without breast cancer. Br J Cancer 1997;76:1112-13.
34. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40. (Pubitemid 28363026)
35. Cserni G. Complete step sectioning of axillary sentinel lymph nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol 2002;55:926-31. (Pubitemid 35454495)
36. Weaver DL. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol 2010;23:S26-32.
37. Mesker WE, Torrenga H, Sloos WC, et al. Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer. J Clin Pathol 2004;57:960-4. (Pubitemid 39213948)
38. Weaver DL, Krag DN, Manna EA, et al. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance study. Cancer 2006;107:661-7. (Pubitemid 44232658)
39. Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006;59:518-22.
40. Khaddage A, Berremila SA, Forrest F, et al. Implementation of molecular intra-operative assessment of sentinel lymph nodes in breast cancer. Anticancer Res 2011;31:585-90.
41. Laia BV, Marcos MB, Refael CM, et al. Molecular diagnosis of sentinel lymph nodes for breast cancer: one step ahead for standardization. Diagn Mol Pathol 2011;20:18-21.
42. Castellano I, Macri L, Deambrogio C, et al. Reliability of whole sentinel lymph node analysis by One-Step Nucleic Acid Amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg 2012;255(2):334-42.
43. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
44. National Comprehensive Cancer Network. Clinical practice guidelines in onologydBreast cancer. Verion 2.2011. http://www.nccn.org/professionals/ physician-gls/pdf/breast.pdf (accessed 3 Jul 2011).
45. Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 2003;39:1654-67. (Pubitemid 36897601)
46. Cserni G. Histopathologic examination of the sentinel lymph nodes. Breast J 2006;12(Suppl 2):S152-6. (Pubitemid 44337462)
47. Dowlatshahi K, Fan M, Snider HC, et al. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997;80:1188-97. (Pubitemid 27407219)
48. Truong PT, Vinh-Hung V, Cserni G, et al. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008;44:1670-7.
49. Montagna E, Viale G, Rotmensz N, et al. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 2009;118:385-94.
50. Amendoeira I, Apostolikas N, Bellocq JP, et al; EC Working Group on Breast Screening Pathology. Quality assurance guidelines for pathology. In: Perry N, Broeders M, de Wolf C, et al, eds. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, 4th edn. Luxemburg: European Comission, 2006:219-311.
51. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011;364:412-21.
52. Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumour cells. Cancer 2004;103:358-67. (Pubitemid 40129296)
53. De Mascarel I, MacGrogan G, Debled M, et al. Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful? Cancer 2008;112:1672-8. (Pubitemid 351551810)
54. Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol 2008;26:258-63.
55. Cserni G, Amendoeira I, Bianchi S, et al. Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. Eur J Cancer 2011;47:887-94.
56. Cserni G. The current TNM classification of breast carcinomas: controversial issues in early breast cancer. MEMO 2011;4:144-8.
57. Zgajnar J, Hocevar M, Podkrajsek M, et al. Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early breast cancer patients. Breast Cancer Res Treat 2006;97:293-9. (Pubitemid 43945759)
58. Cserni G, Gregori D, Merletti F, et al. Non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer: metaanalysis of 25 studies. Br J Surg 2004;91:1245-52. (Pubitemid 39331448)
59. Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009;35:690-5.
60. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003; 98:2307-15. (Pubitemid 37466644)
61. Van la Parra RF, Peer PG, Ernst MF, et al. Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol 2011;37:290-9.
62. Guillen-Paredes MP, Carrasco-Gonzalez L, Chaves-Benito A, et al. [One-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases as an alternative to conventional postoperative histology in breast cancer: A cost-benefit analysis.] Cir Esp 2011;89(7):456-62.
63. Cutress RI, McDowell A, Gabriel FG, et al. Observational and cost analysis of the implementation of breast cancer sentinel node intraoperative molecular diagnosis. J Clin Pathol 2010;63:522-9.
64. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis. Ann Surg 2010;252:426-33.
65. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010;17:1854-61.